Serine protease inhibitors block priming of monocytes for enhanced release of superoxide.
Monocytes freshly isolated from human blood produced large amounts of superoxide when triggered by phorbol ester. After monocytes were cultured for 18-24 hr in endotoxin-free, non-adherent conditions, they produced low amounts of superoxide. Addition of lipopolysaccharide (LPS), interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha), or platelet-activating factor (PAF) at the beginning of culture 'primed' the monocytes, causing them to maintain a high superoxide response for at least 96 hr. Also, in response to LPS, monocytes secreted TNF-alpha. The ability of LPS, IFN-gamma, TNF-alpha or PAF to maintain the high superoxide response was blocked by addition of inhibitors of serine proteases, either 4-(2-aminoethyl)-benzenesulphonyl fluoride (AEBSF) or 3,4-dichloroisocoumarin. AEBSF was most effective at 200 microns, and required 6 hr for maximum effect. AEBSF did not affect phorbol-triggered superoxide release by unprimed monocytes. AEBSF did not affect cell viability, nor did it interfere with the TNF-alpha secretion in response to LPS. An analogue of AEBSF that lacked ability to inhibit proteases did not affect monocyte responses. 3,4-Dichloroisocoumarin blocked priming at a low concentration, 1 microM. We conclude that activity of a monocyte serine protease is required to maintain the high superoxide response in monocytes primed with LPS, IFN-gamma, TNF-alpha, or PAF.
Megyeri
P
P
Dental Research Center, University of Tennessee, Memphis 38163, USA.
Pabst
K M
KM
Pabst
M J
MJ
D018929:Cell Culture Techniques; D003374:Coumarins / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D049934:Isocoumarins; D007700:Kinetics; D008070:Lipopolysaccharides / Q000276:immunology; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology; D013450:Sulfones / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000096926:Benzenesulfonamides
D003374:Coumarins; D049934:Isocoumarins; D008070:Lipopolysaccharides; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; D013450:Sulfones; D013481:Superoxides; D014409:Tumor Necrosis Factor-alpha; C002010:4-(2-aminoethyl)benzenesulfonylfluoride; C097944:4-(2-aminoethyl)benzenesulfonamide; D000096926:Benzenesulfonamides; C046235:3,4-dichloroisocoumarin